Ludk Pour

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;

Maxim Norkin ;

Jan Staub ;

Catriona Byrne ;

Malin Sydvander ;

Enrique M. Ocio ;

Vincent Ribrag , MD;

Ludk Pour ;

10/22/2019

OCEAN: A Phase 3, Randomized, Global Study of Melflufen and Dexamethasone Versus Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Refractory to Lenalidomide

Purpose of the Study: Only 20%-30% of patients with relapsed/ refractory multiple myeloma (RRMM) respond to the next line of treatment, and ultimately most will relapse. Melflufen is a li...

Pieter Sonneveld ;

Fredrik Schjesvold ;

Pawel Robak ;

Viktor Rossjey ;

Sosana Delimpasi ;

Ludk Pour ;

Wojciech Legic ;

Catriona Byrne ;

Galina Salogub ;

Jiri Minarik ;

Johan Harmenberg ;

Paul G. Richardson ;